Nuvation Bio (Nuvation Bio) Current Accrued Expense : $5.30 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio Current Accrued Expense?

Nuvation Bio's Current Accrued Expense for the quarter that ended in Dec. 2023 was $5.30 Mil.

Nuvation Bio's quarterly Current Accrued Expense increased from Jun. 2023 ($9.55 Mil) to Sep. 2023 ($11.86 Mil) but then declined from Sep. 2023 ($11.86 Mil) to Dec. 2023 ($5.30 Mil).

Nuvation Bio's annual Current Accrued Expense increased from Dec. 2021 ($5.57 Mil) to Dec. 2022 ($5.72 Mil) but then declined from Dec. 2022 ($5.72 Mil) to Dec. 2023 ($5.30 Mil).

Nuvation Bio Current Accrued Expense Historical Data

The historical data trend for Nuvation Bio's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Current Accrued Expense Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

1.15

5.57

5.72

5.30

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial											5.72	8.36	9.55	11.86	5.30

Nuvation Bio Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Nuvation Bio Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

NUVB:USA

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).